Despite anti-haemorrhagic therapy with proper doses of activated prothrombin complex
concentrate (aPCC, Feiba®), patients with acquired haemophilia A (AHA) have a …

This study aimed to assess dosage, duration of treatment, as well as the effectiveness and
safety of activated prothrombin complex concentrate (aPCC) in patients with AHA …

In acquired haemophilia A (AHA), risk for recurrent bleeding exists until the inhibitor is
detectable. Thus, patients with persisting inhibitor may benefit from prophylaxis with …

Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …

Background Bypassing agents are the first line therapy in patients with acquired
haemophilia A (AHA). Activated prothrombin complex concentrate (aPCC) proved to be …

Background Currently, the greatest challenge in hemophilia treatment is managing
hemophilia patients with inhibitors. The two main bypassing agents that are used to treat …

Prophylaxis with concentrates of factor VIII has become the standard of care for patients with
severe haemophilia A because of its ability to prevent joint and other bleeding events …

Haemophilia patients with inhibitors can develop bleeding episodes, which are refractory to
monotherapy with either recombinant factor VIIa (rFVIIa) or activated prothrombin complex …

Non‐activated and activated prothrombin complex concentrates (PCC/aPCC) have been
used successfully to treat bleeds in haemophilia patients with inhibitors, but most physicians …

Objective: A cost analysis model was developed to compare annual cost of prophylaxis with
activated prothrombin complex concentrate (aPCC) vs. on‐demand therapy with activated …